Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have ...
Moderna reported better-than-expected 1Q24 revenue of $167 million and its pipeline looks promising. Read my earnings ...
Synopsys VC Verification IP (VIP) for ARM® AMBA® AXI™ provides complete protocol support for AXI3™, AXI4™, AXI4-Lite™, AXI4-Stream™, ACE™, ACE-Lite™ , AHB™ and APB™ interfaces. ... Synopsys® VC ...
The US Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345, Moderna), a vaccine for respiratory syncytial virus (RSV). The mRNA vaccine is approved for adults aged 60 years or ...
The US Food and Drug Administration (FDA) has approved the messenger RNA-based (mRNA) vaccine against respiratory syncytial virus (RSV) for people ages 60 and older. The vaccine, made by ...
Reports of a rare nervous system disorder are "more common than expected" in older U.S. adults who got the new RSV vaccines.